ShopVision | $4,100,000 | (Sep 19, 2025)
Hydrostor | $55,000,000 | (Sep 19, 2025)
Samara(US) | $34,000,000 | (Sep 19, 2025)
Certified by Founder
Lodge
DiogenX
start up
France
- Marseille
- 11/05/2023
- Series A
- $30,056,125
DiogenX is a preclinical stage biotech company committed to a single mission: to discover and develop innovative biologics as new therapeutics options for millions of Diabetic patients around the world.
Our lead program, originating from Dr Patrick Collombat’s laboratory, is based on a new approach targeting beta-cell failure throughout the stimulation of beta-cell functional recovery in diabetes. This novel mode of action will provide a unique solution to rebalance glucose/insulin homeostasis and thus offer clear clinically meaningful benefits.
DiogenX is headquartered in Marseille, with labs in Nice (France).
- Industry Biotechnology
- Website https://diogenx.com/
- LinkedIn https://www.linkedin.com/company/diogenx/
Sevaro | $39,000,000 | (Sep 19, 2025)
Centari | $14,000,000 | (Sep 19, 2025)
Terra Oleo | $3,100,000 | (Sep 19, 2025)
Phia | $8,000,000 | (Sep 19, 2025)
Vibranium Labs | $4,600,000 | (Sep 19, 2025)
Invisible Technologies | $100,000,000 | (Sep 18, 2025)
Stablecore | $20,000,000 | (Sep 18, 2025)
Markup AI | $27,500,000 | (Sep 18, 2025)
Moby | $5,000,000 | (Sep 18, 2025)